Status:
COMPLETED
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
Lead Sponsor:
Pfizer
Conditions:
Pharmacokinetics
Eligibility:
FEMALE
45+ years
Phase:
PHASE4
Brief Summary
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subject...
Eligibility Criteria
Inclusion
- Healthy post-menopausal female subjects, at least 45 years of age, with confirmed post-menopausal status
- Hysterectomized subjects
- Body Mass Index (BMI) less than or equal to 34.0 kg/m2
- Nonsmoker or smoker of fewer than 5 cigarettes per day as determined by history
- An informed consent document signed and dated by the subject
Exclusion
- History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic disease
- Presence or history of deep vein thrombosis or transient ischemic attack
- History of seizure disorder
- Presence or history of glaucoma or increased intraocular pressure
- Allergy to or unable to tolerate tamoxifen, desvenlafaxine, or venlafaxine
- History of substance abuse within 1 year of study
- A positive urine drug screen
- Treatment with an investigational drug within 30 days
- Consumption of grapefruit or grapefruit related citrus fruits
- 12 lead ECG demonstrating QTc \>450 msec at screening
- Pregnant or nursing females
- Use of prescription or nonprescription drugs and dietary supplements
- History of sensitivity to heparin or heparin induced thrombocytopenia
- Severe acute or chronic medical or psychiatric condition or laboratory abnormality
- Use of CYP 2D6 inhibitors and CYP 3A4 inhibitors/inducers
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01189500
Start Date
August 1 2010
End Date
October 1 2010
Last Update
November 7 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Miami, Florida, United States, 33126
2
Pfizer Investigational Site
Miami, Florida, United States, 33134